Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov sold 2,431 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of C$6.67, for a total value of C$16,212.34.
Rostislav Christov Raykov also recently made the following trade(s):
- On Wednesday, September 4th, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$7.45, for a total value of C$18,115.81.
Fennec Pharmaceuticals Price Performance
TSE:FRX opened at C$6.26 on Friday. The stock has a market capitalization of C$171.27 million, a PE ratio of 69.56 and a beta of 0.26. Fennec Pharmaceuticals Inc. has a 1-year low of C$6.14 and a 1-year high of C$15.43. The firm has a fifty day simple moving average of C$7.46 and a 200 day simple moving average of C$9.79. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68.
Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share for the quarter, missing the consensus estimate of C$0.08 by C($0.35). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 5.59%. The firm had revenue of C$9.94 million for the quarter, compared to analyst estimates of C$18.67 million. On average, research analysts expect that Fennec Pharmaceuticals Inc. will post 0.6025751 EPS for the current fiscal year.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Next opportunity for crypto millions
From Crypto 101 Media | Ad
"Uptober" is here, and it's not just a clever name.
Historically, October ignites crypto's most explosive gains. This year could be off the charts.
Don't let this opportunity pass you by. In crypto, timing is everything.
Go here to discover the #1 crypto set to dominate Uptober.
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
